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Abstract
Background: In medical practice, it is generally accepted that the 'effect model' describing the
relationship between baseline risk and risk under treatment is linear, i.e. 'relative risk' is constant.
Absolute benefit is then proportional to a patient's baseline risk and the treatment is most effective
among high-risk patients. Alternatively, the 'effect model' becomes curvilinear when 'odds ratio' is
considered to be constant. However these two models are based on purely empirical
considerations, and there is still no theoretical approach to support either the linear or the non-
linear relation.
Presentation of the hypothesis: From logistic and sigmoidal Emax (Hill) models, we derived a
phenomenological model which includes the possibility of integrating both beneficial and harmful
effects. Instead of a linear relation, our model suggests that the relationship is curvilinear i.e. the
moderate-risk patients gain most from the treatment in opposition to those with low or high risk.
Testing the hypothesis: Two approaches can be proposed to investigate in practice such a
model. The retrospective one is to perform a meta-analysis of clinical trials with subgroups of
patients including a great range of baseline risks. The prospective one is to perform a large clinical
trial in which patients are recruited according to several prestratified diverse and high risk groups.
Implications of the hypothesis: For the quantification of the treatment effect and considering
such a model, the discrepancy between odds ratio and relative risk may be related not only to the
level of risk under control conditions, but also to the characteristics of the dose-effect relation and
the amount of dose administered. In the proposed approach, OR may be considered as constant
in the whole range of Rc, and depending only on the intrinsic characteristics of the treatment.
Therefore, OR should be preferred rather than RR to summarize information on treatment
efficacy.
Background
The questions about whether and how the treatment ben-
efit varies according to a patient's certain characteristics
have deserved several works recently. [1-4] Available evi-
dence as well as theoretical considerations support such
links. Baseline risk (i.e. the risk of outcome for a patient
under no treatment conditions) is used as a convenient
summary of numerous characteristics which may be
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potential risk factors. The relation found between baseline
risk and risk under treatment (quoted as the 'effect model'
of the treatment [5]) indicates that some patients respond
better, i.e. with a greater absolute risk reduction, to a given
treatment than others do. L'Abbé plot [6] is a convenient
graphical representation of the 'effect model', expressing
on the x axis the risk of event under control conditions
(Rc) and on the y axis the risk of event under treatment
(Rt) (see Figure 1). The identity line corresponds with no
treatment effect. For the dots below this line, Rt is lower
than Rc and the treatment is beneficial. While for those
falling above this line, the treatment seems unfavorable. A
regression line may be estimated assuming the relative
risk (RR) is constant, whereas absolute risk reduction
(ARR) varies, possibly almost proportionately, with the
baseline risk of patients. However, several problems
accompany the linear relation between Rc and Rt : firstly,
the linear model is purely empirical ; secondly, it does not
take into account the range of variation of Rc and Rt, lim-
ited from 0 to 1 ; lastly, the validity of linear extrapolation
for the patients in high risk (i.e. Rc > 0.5) remains most
often unknown.
A simulation approach [7] based on numerical models of
drug action has explored the whole range of Rc and sug-
gested a curvilinearity at least in some settings. However,
there is still no theoretical approach to support such a
non-linear relation. Consequently, we propose an alterna-
tive approach to revisit the relationship between Rc and
Rt, based on a phenomenological model that includes the
possibility of integrating both beneficial and harmful
therapeutic effects.
L'Abbé plot showing the relationships between Rc (x axis) and Rt (y axis) presented in the condition that the 'effect model' is  linear Figure 1
L'Abbé plot showing the relationships between Rc (x axis) and Rt (y axis) presented in the condition that the 
'effect model' is linear. The identity line (Rt = Rc) corresponds with no treatment effect. Below this line, Rt is lower than Rc 
and the treatment is beneficial. Above this line the treatment is deleterious. A regression line may be estimated assuming the 
relative risk (RR) as a constant 'a' (Rt = a*Rc). In case of a full linear model (Rt = a*Rc + b), the treatment is beneficial for levels 
of Rc greater than the threshold, and deleterious for levels of Rc lower than the threshold. X axis: risk of event under control 
conditions (Rc), Y axis: risk of event under treatment (Rt).
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Presentation of the hypothesis
First, let us assume that the probability (risk) of the out-
come follows a logistic model [8]:
Where R corresponds to the probability of the outcome,
β0 and β1 are the intercept and slope of linear function
respectively, and E is the pharmacodynamic effect (or sim-
ilarly a risk factor of the spontaneous outcome).
Then let us suppose that the treatment affects E through a
direct pharmacodynamic dose-response model (i.e. the
sigmoidal Emax model or Hill model [9]) :
where E is the pharmacodynamic effect, E0 represents
baseline value of E, Emax  is the maximum theoretical
effect, D is the dose, ED50 is the dose at which 50% of the
maximum effect is achieved, and γ  is the sigmoidicity
parameter.
Then, in treated subjects, the probability of outcome Rt
and the treatment parameters are linked by :
Letting D = 0 for the patients under control conditions, Rc
is given by
Transforming equation (4) and substituting into (3), we
have
a model with Rc as independent variable, Rt as dependent
variable, and β1, Emax, ED50, D, and γ as parameters.
Since   is the odds ratio (OR) of the outcome,
equation (5) becomes
Therefore, OR which represents the size of treatment effi-
cacy, does not vary with Rc. OR is here a constant only
determined by pharmacotherapeutic parameters. This
remains also true in case of an active control therapy (D ≠
0).
Figure 2A shows the corresponding relations between Rc
and Rt or ARR (left and right column respectively), assum-
ing OR as a constant. In Figure 2B (left column), the quan-
titative treatment effect is shown as a function of the dose
D. This effect is expressed either as an OR (thick line what-
ever the level of Rc) or a RR (thin lines for increasing levels
of Rc). Compared with RR, the difference in the estima-
tion of the treatment effect using OR is greater for high
levels of Rc, and also depends on the value of the admin-
istered dose D. The same results are shown in Figure 2B
(right column) using ARR as the expression of the quanti-
tative treatment effect. Additional simulations could be
performed considering the other parameters of the dose-
effect relation (i.e. Emax, ED50 and γ).
For a treatment with two independent mechanisms (one
for the expected beneficial effect and the other for toxicity)
and contributing to the same outcome (e.g. death), OR of
benefit (OR1) or harm (OR2) can be expressed with its
own pharmacological parameters as:
where i = 1 for benefit and i = 2 for harm.
Since the joint probability of two independent events is
calculated by P = P1 + P2 - P1·P2, Rt and Rc can be written
by :
Rt = Rt1 + Rt2 - Rt1·Rt2 and Rc = Rc1 + Rc2 - Rc1·Rc2.
Then from models (7) and (8), for a treatment with one
or two effects respectively, Rt and other measures of treat-
ment effect, such as RR and ARR, can be easily translated
and the relationships between baseline risk and treatment
effect can be graphically simulated over the whole range
of Rc (Figure 2C). The U-shape relation between Rc and Rt
indicates that the patients with moderate risk obtain most
from the treatment while those at highest risk benefit less
or not at all. For a treatment involving two independent
mechanisms, a harmful effect is observed in low-risk
groups, and treatment effects under different doses show
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Figure 2 (see legend on next page)
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the potential difficulties of choosing an optimal dose for
a patient, especially for those in low baseline risk.
Testing the hypothesis
Two approaches (retrospective and prospective) can be
proposed in order to investigate in practice such a non-lin-
ear 'effect model'. The retrospective one is to perform a
meta-analysis of clinical trials with subgroups of patients
with a great range of baseline risks. An alternative is to
conduct a meta-analysis of individual patient data, a prac-
tical way of detecting differential treatment effects among
various risk groups. [10] The prospective approach is to
perform a large clinical trial ('megatrial') or several trials,
in which patients are recruited according to several diverse
risk groups that are prestratified depending on the infor-
mation taken from previous small trials [11]. Severe
patients, who are usually excluded from clinical trials, will
be then preferentially included to detect the real treatment
effect in high-risk conditions.
Implications of the hypothesis
Using such a phenomenological approach based on the
logistic and sigmoidal Emax (Hill) models, we observe a
non-linear relation between Rc and Rt, that confirms pre-
vious results. [7,12]
These results are however strongly dependent on the
underlying models considered. Logistic regression, one of
a class of models known as generalized linear models, is a
type of predictive model that can be used with two types
of target variables : a categorical one that has exactly two
categories (i.e., a binary or dichotomous variable), or a con-
tinuous one that has values in the range 0 to 1 represent-
ing probability values or proportions; explanatory
variables can be either categorical or quantitative. The log
odds is then a linear function of the explanatory varia-
ble(s), leading to an OR constant. This model is now used
extensively in the medical science, where a clinical out-
come is in most cases binary (e.g. death/alive, event/no
event). The dose-concentration-effect model (e.g. Hill
model) is based on the law of mass-action and on receptor
occupancy theory, supposing a reversible drug pharmaco-
dynamic effect which is related to the clinical (binary)
outcome. Depending on the biological effects of drugs
and their mechanisms of action, such assumptions may
not be always valid, particularly in case of irreversible
mechanisms, tolerance/rebound phenomena, and syner-
gistic/antagonist effects.
For most patients (e.g. those in low or moderate risk), one
can assume a linear relation with an absolute benefit pro-
portional to the baseline risk. However for high-risk
patients, appropriate data are required to show up
whether it remains proportional or decreases to zero. The
values of OR and RR may consequently differ according
not only to the level of risk under control conditions (Rc),
but also to the characteristics of the dose-effect relation
and the amount of the dose chosen. In the proposed
approach, OR may be considered as constant in the whole
range of Rc, and depending only on the intrinsic charac-
teristics of the treatment. Therefore, OR should be pre-
ferred to summarize information on treatment efficacy.
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A. Phenomenologically based simulation of the relationships between Rc and Rt (left column) or ARR (right column) presented  in the condition that the treatment effect is beneficial Figure 2 (see previous page)
A. Phenomenologically based simulation of the relationships between Rc and Rt (left column) or ARR (right 
column) presented in the condition that the treatment effect is beneficial. The dotted line in the plots corresponds 
to the no effect line; the dash, solid, and dotted-dash line represent three different theoretical doses. The pharmacotherapeutic 
parameters, Emax, ED50, γ, and β1, for beneficial effect, are -30, 100, 3, and 0.137 respectively. The three considered doses were 
fixed at 70, 100, and 120. X axis: risk of event under control conditions (Rc), Y axis: risk of event under treatment (Rt) (left col-
umn), absolute risk reduction (ARR), (right column). B. Phenomenologically based simulation of the relationships between dose 
D and quantitative treatment effect (left column) or ARR (right column) presented in the condition that the treatment effect is 
beneficial. The thick line corresponds to the relation between D and odds-ratio (OR) whatever the level of Rc, and the three 
thin lines to the relation between D and risk ratio (left column) or ARR (right column) for three levels of Rc (0.3, 0.6 and 0.9, 
dash, dotted and solid lines respectively). X axis: dose D, Y axis: OR or RR (thick or thin lines respectively) (left column), ARR 
(right column). C. Phenomenologically based simulation of the relationships between Rc and Rt (left column) or ARR (right col-
umn) presented in the condition that the treatment effect is biphasic. The dotted line in the plots corresponds to the no effect 
line; the dash, solid, and dotted-dash line represent three different theoretical doses. The pharmacotherapeutic parameters, 
Emax, ED50, γ, and β1, for beneficial effect, are -30, 100, 3, and 0.137 respectively, and those for deleterious effect are 10, 250, 2, 
and 1.79 respectively. The baseline risk of harm (Rc2) is 0.0035. The three considered doses were fixed at 70, 100, and 120. X 
axis: risk of event under control conditions (Rc), Y axis: risk of event under treatment (Rt) (left column), absolute risk reduc-
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